Literature DB >> 12695680

Cytotoxic ribonucleases and RNA interference (RNAi).

Barbara Ardelt1, Wojciech Ardelt, Zbigniew Darzynkiewicz.   

Abstract

Several cytotoxic ribonucleases (CRs), homologs of the pancreatic RNase A, have been isolated from amphibian oocytes or embryos. Of them, onconase (Onc), the CR that shows antitumor properties and is in phase III clinical trials, was the most extensively researched. Degradation of tRNA by Onc internalized into cells that leads to inhibition of protein synthesis is considered the mechanism of its cytotoxicity. Several findings, however, cannot be explained by nonspecific decline in protein synthesis alone and suggest additional or alternative mechanism(s). We postulate therefore that miRNAs and/or RNA interference (RNAi) may also be targets of CRs. The following arguments support this postulate: (A) miRNAs and siRNAs appear to be unprotected by proteins and therefore, as tRNA, accessible and degradable by CRs; (B) Onc has preferred cleavage sites on tRNAs: their cleavage may generate segments of dsRNA that interfere with translation. Analogous to Dicer, thus, small RNAs with interfering properties may be generated by CRs within the cell; (C) CRs are abundant in oocytes and during embryonic development; their role there is unknown. Since cells undergo perpetual differentiation during embryogenesis it is likely that the function of CRs is to provide additional level of regulation of gene expression via the mechanisms listed in (A) and/or (B).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695680     DOI: 10.4161/cc.2.1.232

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  25 in total

1.  The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.

Authors:  Pere Tubert; Montserrat Rodríguez; Marc Ribó; Antoni Benito; Maria Vilanova
Journal:  Invest New Drugs       Date:  2010-03-30       Impact factor: 3.850

2.  Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.

Authors:  Barbara Ardelt; Wojciech Ardelt; Piotr Pozarowski; Jan Kunicki; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2007-09-12       Impact factor: 4.534

Review 3.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 4.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

5.  Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

Authors:  Deborah A Altomare; Susanna M Rybak; Jianming Pei; Jacob V Maizel; Mitchell Cheung; Joseph R Testa; Kuslima Shogen
Journal:  BMC Cancer       Date:  2010-02-05       Impact factor: 4.430

Review 6.  RNA dust: where are the genes?

Authors:  Piero Carninci
Journal:  DNA Res       Date:  2010-03-07       Impact factor: 4.458

7.  The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

Authors:  Hong Zhao; Barbara Ardelt; Wojciech Ardelt; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2008-10-25       Impact factor: 4.534

8.  Structural basis for catalysis by onconase.

Authors:  J Eugene Lee; Euiyoung Bae; Craig A Bingman; George N Phillips; Ronald T Raines
Journal:  J Mol Biol       Date:  2007-10-04       Impact factor: 5.469

Review 9.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

10.  Zebrafish RNase T2 genes and the evolution of secretory ribonucleases in animals.

Authors:  Melissa S Hillwig; Ludmila Rizhsky; Ying Wang; Alisa Umanskaya; Jeffrey J Essner; Gustavo C MacIntosh
Journal:  BMC Evol Biol       Date:  2009-07-20       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.